

Figure 1: Giemsa ,HP: Hemophagocytosis (Macrophages Engulfing Erythroid Cells)




Figure 4: Giemsa ; HP: - Histiocytic Proliferation




Figure 2: Giemsa ; HP : - Hemophagocytosis)




Figure 5: Giemsa ; LP :- Lympho-Histiocytic Proliferation




Figure 3: Giemsa , LP: - Macrophage Engulfing Many Erythroid Cells.

3. Discussion

Hemophagocytic lymphohistiocytosis (HLH) is a rare life threatening disease of the immune system characterised by proliferation of activated T lymphocytes and macrophages which are morphologically benign. It has 2 types Primary/Familial HLH & Secondary HLH¹

The current (2008) diagnostic criteria for FAMILIAL HLH^{3,4,5}

1. A molecular diagnosis consistent with HLH. These include the identification of pathologic mutations of PRF1, UNC13D, or STX11.

OR

2. Fulfillment of five out of the eight criteria below:

- a) Fever (>100.4 degrees F)
- b) Splenomegaly
- c) Cytopenias affecting at least two of three lineages in the peripheral blood:
 - Haemoglobin < 9 g/100 ml (in infants < 4 weeks: haemoglobin < 10 g/100 ml)
 - Platelets < $100 \times 10^9/L$
 - Neutrophils < $1 \times 10^9/L$

- d) Hypertriglyceridemia (fasting, greater than or equal to 265 mg/100 ml) and/or hypofibrinogenemia (\leq 150 mg/100 ml)
- e) Ferritin \geq 500 ng/ml
- f) Haemophagocytosis in the bone marrow, spleen or lymph nodes
- g) Low or absent natural killer cell activity
- h) Soluble CD25 (soluble IL-2 receptor) $>$ 2400 U/ml.

In addition, in the case of familial HLH, no evidence of malignancy should be apparent.

A 26 days boy presented with hepatosplenomegaly, lymphadenopathy, Jaundice and light hairs. There was history of sibling death with similar complaints. All the typical clinical features of HPS were present in this case. There was no evidence of Malignancy or any Viral, bacterial & fungal infections ruling out Secondary HLH. The common age of HPS is between 5-8 months but in this case Neonate was affected making it a Rare case presentation⁶

Clinical signs and laboratory abnormalities associated with HPS⁵

<u>Clinical sign% of patient affected</u>	
Fever	60-100
Splenomegaly*	35-100
Hepatomegaly	39-97
Lymphadenopathy	17-52
Rash	3-65
Neurologic signs	7-47

<u>Laboratory abnormality</u>	
Anemia*	89-100
Thrombocytopenia*	82-100
Neutropenia*	58-87
Hypertriglyceridemia*	59-100
Hypofibrinogenemia*	19-85
Hyperbilirubinemia	74-19

The various studies on HLH gave the following conclusion which was very well correlated in this case report⁵. The B.M. aspirate shows good number of hypercellular B.M. fragments. LymphoHistiocytic proliferation is very prominent. Erythroid cells, lymphocytes & Platelets are Phagocytosed by histiocytes. No Giant granules noted ruling out CHS.

The Diagnosis was confirmed by Molecular testing which showed Mutation in PRF1 gene. So this case falls under FHS type⁶

Differential Diagnosis

Secondary HLH Macrophage-activation syndrome or other primary immuno deficiencies that present with hemophagocytic lymphohistiocytosis, such as X-linked lympho proliferative disease. Autoimmune lympho proliferative syndrome.⁷

The diagnosis of acquired or secondary HLH is usually made in association with infection by viruses, bacteria, fungi or parasites or in association with lymphoma, autoimmune disease, or metabolic disease.

A major differential of HLH is Griscellis syndrome (type 2) which have mutations in RAB27A. This is a rare (less than 100 reported cases) autosomal recessive disorder characterized by partial albinism, hepatosplenomegaly, pancytopenia, hepatitis, immunologic abnormalities, and lymphohistiocytosis. Most cases have been diagnosed between 4 months and 7 years of age.

4. Conclusion

Familial HPS is a very rare entity. There is a considerable overlap of clinical & pathological findings of Familial HPS & Secondary HPS, Griscelli syndrome & Macrophage activation syndromes possessing a great diagnostic challenge.

The very rare nature of the disease & its grave prognosis merits its Reporting.

5. Funding: No funding sources

6. Conflict of interest: None declared

7. Ethical approval: Not required

References

- [1] Ronald Hoffman, Farhad R. Chapter 17 Phagocytes, in Postgraduate Hematology by Victor Hoffbrand, Daneal Catovsky, 2007; 6th ed. 300-327
- [2] Janka G. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 1983; 140: 221-30.
- [3] Fisman, David N. "Hemophagocytic syndromes and infection". Emerging Infectious Dis. (2000) 6 (6): 6018-25
- [4] Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden pathology and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991; 80: 428-35
- [5] Reiner A, Spivak J. Hemophagocytic histiocytosis: areport of 23 new patients and a review of the literature. Medicine 1988; 67: 369-88
- [6] Stepp SE, Le Deist, perforin gene defects in Familial HLH, 1999 286: 1957-1959
- [7] Gupta S, Weitzman S, Primary & Secondary Lymphohistiocytosis Clinical features, Pathogenesis and therapy Expert review Clinical Immunol 2010, 6: 137-154
- [8] Rudman Spergel A, Walkovich K, Price S et al. (November 2013). "Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis". Pediatrics 132 (5)